Abstracts tagged "Antiphospholipid syndrome and renal disease"

Abstract Number: 169 • 2018 ACR/ARHP Annual Meeting
Prognosis of Patients with Antiphospholipid Syndrome Nephropathy
Clémentine Rousselin¹, Zahir Amoura², Alexandre Karras³, Dominique Guerrot⁴, Jean-Jacques Boffa⁵, Guillaume Canaud⁶, Stanislas Faguer⁷, Eric Auxenfants⁸, Noémie Jourde-Chiche⁹, Marc Lambert¹⁰ and Thomas Quémeneur¹¹, ¹Department of internal medicine, Hopital de Valenciennes, France, Valenciennes, France, ²Université Pierre et Marie Curie, Paris, France, ³Department of Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, Paris, France, ⁴Service de Néphrologie, Department of Nephrology, Centre Hospitalier de Rouen, France, Rouen, France, ⁵Department of Nephrology, Hôpital Tenon, France, Paris, France, ⁶Department of Nephrology and Transplantation, Necker-Enfants Malade, Université Paris Descartes, Sorbonne Paris Cité, INSERM U1151, Necker-Enfants Malades Hospital, Paris, France AP-HP, Paris, France, PARIS, France, ⁷Nephrology, CHU, Toulouse, France, ⁸CH Roubaix - Médecine interne, Roubaix, France, ⁹Nephrology, Department of Nephrology, AP-HM, CHU Conception, Marseille, France, Marseille, France, ¹⁰Lille, Lille, France, ¹¹Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France
Background/Purpose: Antiphospholipid syndrome (APS) is associated with several patterns of renal involvement. Among them, antiphospholipid nephropathy (APSN) is a rare but specific pattern resulting from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].